Cutaneous Lichen Amyloidosis When Oral Retinoids Have Not Achieved Adequate Response

This protocol applies to patients with cutaneous lichen amyloidosis who have undergone a full course of oral retinoid therapy and have not achieved satisfactory improvement by the end of that treatment period.

Prior treatment failure: Oral retinoids — including etretinate, acitretin, isotretinoin, or alitretinoin — given over four to six months did not result in adequate reduction of pruritus and flattening of the papules. These are the expected endpoints for that treatment line; their non-achievement defines the need for escalation.

When oral retinoids fall short, the next step draws on a range of alternative topical and systemic agents. The full protocol specifies which options are appropriate in this context — the complete regimen is available via the link below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.4103/pigmentinternational.pigmentinternational_

Tocoretinate, a hybrid compound of retinoic acid and tocopherol, was shown to be beneficial in both LA and MA lesions in a case series involving 10 patients.
Topical calcipotriol, topical tacrolimus 0.1%, oral low dose cyclophosphamide, oral cyclosporin, have been tried with varying degrees of success.

View source ↗